Spotlight Therapeutics, Inc. — Form D
Spotlight Therapeutics, Inc. of Hayward, CA, a company, filed a Form D exempt-offering notice with the SEC on 2022-01-05. The offering totals $65.0M, of which $32.2M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2022-01-05
- Form: D
- Accession: 0001726495-22-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $65.0M
- Amount sold: $32.2M
- Remaining: $32.8M
- Investors: 11
- Date of first sale: 2021-12-10
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-427880
Issuer
- Name: Spotlight Therapeutics, Inc.
- CIK: 0001726495
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2017
- Address: 3953 Point Eden Way, Hayward, CA, 94545
- Phone: (510) 405-5209
Officers, directors & promoters (12)
| Name | Role | Location |
|---|
| Jacob Corn | Director | Hayward, CA |
| Patrick David Hsu | Director | Hayward, CA |
| Alexander David Marson | Director | Hayward, CA |
| Krishna David Yeshwant | Director | Hayward, CA |
| Mary Haak-Frendscho | Executive Officer | Hayward, CA |
| Blake Byers | Director | Menlo Park, CA |
| Alexander Marson | Director | San Francisco, CA |
| Alexander Marson | Executive Officer | San Francisco, CA |
| Mary Haak-Frendscho | Director | Hayward, CA |
| Blake David Byers | Director | Hayward, CA |
| Mary HaakFrendscho | Director | Hayward, CA |
| Mary HaakFrendscho | Executive Officer | Hayward, CA |
Other filings by this issuer (3)
More